Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Liabilities from Discontinued Operations: 2018-2023

Historic Liabilities from Discontinued Operations for Aclaris Therapeutics (ACRS) over the last 6 years, with Dec 2023 value amounting to $2.2 million.

  • Aclaris Therapeutics' Liabilities from Discontinued Operations changed negligibly% to $2.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.2 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.2 million for FY2023, which is negligibly% changed negligibly from last year.
  • As of FY2023, Aclaris Therapeutics' Liabilities from Discontinued Operations stood at $2.2 million, which was down 0.00% from $2.2 million recorded in FY2022.
  • Over the past 5 years, Aclaris Therapeutics' Liabilities from Discontinued Operations peaked at $4.2 million during FY2019, and registered a low of $2.2 million during FY2021.
  • Over the past 3 years, Aclaris Therapeutics' median Liabilities from Discontinued Operations value was $2.2 million (recorded in 2023), while the average stood at $2.2 million.
  • Data for Aclaris Therapeutics' Liabilities from Discontinued Operations shows a maximum YoY tumbled of 44.10% (in 2019) over the last 5 years.
  • Over the past 5 years, Aclaris Therapeutics' Liabilities from Discontinued Operations (Yearly) stood at $4.2 million in 2019, then decreased by 25.16% to $3.1 million in 2020, then decreased by 29.22% to $2.2 million in 2021, then remained steady at $2.2 million in 2022, then remained steady at $2.2 million in 2023.